drugset / Trial / NCT00313768
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Timeline
- Start
- 2005-12
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | agatolimod | Oligonucleotide (other) | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |